Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tian Jing Formula plus Femoston for premature ovarian insufficiency with kidney deficiency
ChiCTR2400090118Phase 2Recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Bushen Tianjing and estradiol in ovarian hypofunction (POI) (2 arms), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoint: Follicle stimulating hormone. Started Sep 2024; status: recruiting.
02
Drugs
Bushen Tianjingestradiol
03
Conditions
ovarian hypofunction (POI)
Beyond the preview
Go deeper on ChiCTR2400090118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090118.